Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Allotment
Orchid Pharma's Board approved the allotment of 4.46 crore new equity shares to eligible shareholders of Dhanuka Laboratories Limited, completing a scheme of amalgamation. The new shares will rank pari-passu with existing shares.
Aug 01 2026 13:50:57
Orchid Pharma Ltd - 524372 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 01, 2026
Orchid Pharma's board approved the issuance and allotment of 4.46 crore fully paid-up equity shares of ₹10 each to eligible shareholders of Dhanuka Laboratories Limited under the amalgamation scheme. This action increased the company's paid-up share capital to ₹59.88 crore. The new shares will be listed on BSE and NSE.
Aug 01 2026 13:46:35
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 01, 2026
Orchid Pharma's Board of Directors is scheduled to meet on August 01, 2026. The key agenda item for this meeting is the consideration and approval of the allotment of fully paid-up equity shares to eligible shareholders of Dhanuka Laboratories Limited, following the Scheme of Amalgamation.
Jul 28 2026 18:47:02
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Orchid Pharma announced its amalgamation scheme became effective on July 10, 2026. This scheme involves the dissolution of Dhanuka Laboratories Limited and the issuance of new shares based on a 161:5 exchange ratio.
Jul 10 2026 20:20:39
Orchid Pharma Ltd - 524372 - Board Meeting Outcome for Intimation Under Regulations 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 As Amended ("SEBI Listing Regulations").
Orchid Pharma announced the amalgamation scheme became effective on July 10, 2026. The authorized share capital has increased to Rs.164.51 crore. A record date of July 23, 2026, has been fixed for issuing new shares to shareholders of the amalgamating company.
Jul 10 2026 19:39:45
Orchid Pharma Ltd - 524372 - Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company/Company') And Their Respective Shareholders
And Creditors ('The Scheme') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 '(SEBI Listing Regulations)', As Amended.
Orchid Pharma's scheme of amalgamation with Dhanuka Laboratories Limited is now effective as of July 10, 2026. The NCLT order sanctioning the scheme has been filed with the Registrar of Companies, leading to Dhanuka Laboratories' dissolution.
Jul 10 2026 19:33:12
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Orchid Pharma entered a licensing and supply agreement with Pharmasyntez JSC, Russia. This deal commercializes their novel antibiotic Exblifep® in Russia, aiming for USD 178 million in revenue over the next 10 years.
Jul 07 2026 19:27:50
Read More